Article

There are strong research activities in the field of dysimmune neuropathies. In
Guillain-Barre syndrome, new pathophysiological mechanisms have been demonstrated
with the potential development of new therapies, a clinical prediction model is
applicable early in the course of disease, and under investigation are new
treatment strategies with adapted intravenous Ig dosages. In chronic inflammatory
demyelinating polyneuropathies, current diagnostic tests are discussed but
biomarkers are needed, such as histological changes or differential gene
expression in nerve or skin biopsies. The exploration of novel therapeutic
approaches including monoclonal antibodies and oral immunosuppressants, known
from multiple sclerosis studies, suggests new approaches to treatment. Changes of
the peripheral nerves on MR imaging are better known and the usefulness of serum
antibodies is reviewed.
CI - Copyright (c) 2012 Elsevier Masson SAS. All rights reserved.

Langue : FRANCAIS